Jeffrey M Gardner

US Patent:

20220275017, Sep 1, 2022

Filed:

Mar 14, 2022

Appl. No.:

17/694180

Inventors:

- New York City NY, US
Eric K. CHEA - Flushing NY, US
Derek S. TAN - New York NY, US
Jason S. LEWIS - New York NY, US
Jeffrey R. GARDNER - New York NY, US

International Classification:

C07H 15/256
A61K 39/39
A61K 45/06
A61K 31/7024
C07H 15/18
C07H 15/24
A61K 31/704

Abstract:

Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.

US Patent:

20220184207, Jun 16, 2022

Filed:

Mar 4, 2022

Appl. No.:

17/687094

Inventors:

- Lincoln NE, US
Jeffrey GARDNER - New York NY, US

Assignee:

ADJUVANCE TECHNOLOGIES, INC. - Lincoln NE

International Classification:

A61K 39/39
A61K 39/00
A61K 31/704

Abstract:

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases and cancers.

US Patent:

20230131867, Apr 27, 2023

Filed:

Sep 19, 2022

Appl. No.:

17/947716

Inventors:

- New York NY, US
Michelle ADAMS - Waterville OH, US
Kai DENG - Guilderland NY, US
Philip LIVINGSTON - New York NY, US
Eric CHEA - Flushing NY, US
Lars Ulrik NORDSTROEM - New York NY, US
William WALKOWICZ - Brooklyn NY, US
Jeffrey GARDNER - New York NY, US
Derek TAN - New York NY, US

International Classification:

C07H 15/256
C07H 13/08
A61K 31/7024
A61K 31/704
C07H 15/24
A61K 39/385

Abstract:

The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

US Patent:

20210338635, Nov 4, 2021

Filed:

Jul 16, 2021

Appl. No.:

17/378052

Inventors:

- New York NY, US
Jeffrey R. GARDNER - New York NY, US

International Classification:

A61K 31/397
A61K 9/00
A61K 39/25

Abstract:

The present application relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disease or disorder, for example multiple sclerosis (MS).

US Patent:

20210299237, Sep 30, 2021

Filed:

Apr 13, 2018

Appl. No.:

16/604867

Inventors:

- New York NY, US
Jeffrey GARDNER - New York NY, US
Lars NORDSTROEM - New York NY, US
William WALKOWICZ - Brooklyn NY, US
J Tyler MARTIN - Roca NE, US
Weidong Zhang - Albany NY, US

Assignee:

ADJUVANCE TECHNOLOGIES, INC. - New York NY

International Classification:

A61K 39/00
C07H 1/08
C07H 15/18
A61K 39/05
A61K 39/08
A61K 39/09
A61K 39/02
A61K 39/29
A61K 39/39
A61P 31/20
A61P 31/04

Abstract:

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

US Patent:

20210283248, Sep 16, 2021

Filed:

Apr 25, 2018

Appl. No.:

16/608296

Inventors:

- Lincoln NE, US
- New York NY, US
Jeffrey GARDNER - New York NY, US
J Tyler MARTIN - Roca NE, US

Assignee:

Adjuvance Technologies, Inc. - Lincoln NE
Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

A61K 39/39
A61K 45/06

Abstract:

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

US Patent:

20210244708, Aug 12, 2021

Filed:

Feb 5, 2021

Appl. No.:

17/168397

Inventors:

- New York NY, US
Jeffrey R. GARDNER - New York NY, US

International Classification:

A61K 31/397
A61K 39/25
A61K 9/00

Abstract:

The present application relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disease or disorder, for example multiple sclerosis (MS).

US Patent:

20210070796, Mar 11, 2021

Filed:

Apr 20, 2020

Appl. No.:

16/853393

Inventors:

- New York City NY, US
Eric K. Chea - Flushing NY, US
Derek S. Tan - New York NY, US
Jason S. Lewis - New York NY, US
Jeffrey R. Gardner - New York NY, US

International Classification:

C07H 15/256
A61K 39/39
A61K 45/06
A61K 31/7024
C07H 15/18
C07H 15/24
A61K 31/704

Abstract:

Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.